Roivant Sciences (ROIV) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategy

• Focuses on late-stage therapeutics, especially in immunology and inflammation, with a $9B market cap and $6B in cash.

• Operates through a portfolio of Vants, which are mostly wholly owned subsidiaries for drug development.

• Prioritizes identifying promising drugs and advancing them through late-stage clinical development.

• Emphasizes flexibility and opportunism in portfolio building, avoiding a single scientific dogma.

• Plans to allocate about a third of cash to the current pipeline, a third to new business development, and return $2B to shareholders.

Key pipeline programs and clinical progress

• VTAMA, a topical for psoriasis, is annualizing $80M+ in sales, with a PDUFA date for atopic dermatitis (AD) later this year.

• AD market is four times larger than psoriasis, with differentiated data and potential for multi-billion dollar sales.

• FcRn franchise includes IMVT-1402 and batoclimab, with deep IgG suppression and subcutaneous administration advantages.

• Batoclimab phase III data in myasthenia gravis expected early next year; IMVT-1402 pivotal program in Graves' disease launching soon.

• Mosliciguat in PH-ILD shows best-in-class PVR data, targeting a large, underserved market.

Competitive positioning and differentiation

• VTAMA faces limited competition in pediatric AD, with most rivals not indicated for children under four.

• FcRn programs offer deeper IgG suppression and more convenient administration compared to competitors.

• In myasthenia gravis, market share gains depend on superior efficacy and patient preference for subcutaneous delivery.

• PH-ILD market familiarity and strong clinical proxies (PVR) support optimism for mosliciguat.